CJC-1295 Ipamorelin Side Effects: Findings From the Human Research
Published human studies found CJC-1295 side effects that were largely mild, namely injection-site reactions, headache and gut complaints, and the 2006 trials in healthy volunteers recorded no serious adverse reactions. Ipamorelin was well tolerated in a phase 2 surgical trial, though it missed its efficacy endpoint. Past those findings there is very little, and nothing at all on the two compounds used together.
Buy CJC-1295 and Ipamorelin Knowing They Hit Different Receptors
The blend is often discussed as though it were a single drug, but it is two. CJC-1295 is a growth hormone releasing hormone (GHRH) analogue working at the GHRH receptor found in the anterior pituitary. Ipamorelin, by contrast, is the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2, and it works at the ghrelin receptor (GHS-R1a). Each drives growth hormone release down its own pathway, which is precisely why researchers combine them, and it is also why the side effect evidence for each must be looked at on its own.
CJC-1295 is also available in two versions. The one used in human trials includes a Drug Affinity Complex (DAC), a reactive linker that attaches the peptide to albumin in circulation and lengthens its half-life to roughly a week. What is generally sold as "CJC-1295 No DAC" is modified GRF(1-29), the same 29-residue GHRH fragment carrying enzyme-resistant substitutions but lacking the albumin anchor. The chemistry is explained fully in our guide to CJC-1295 DAC vs No DAC, and for side effects the essential fact is that all published human trials used the DAC version. You can buy CJC-1295 with DAC online in Australia as a 5 mg vial, the version those human trials studied.
Shop CJC-1295 Australia With the Human Trial Data in Hand
The key reference is Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism, 2006. The paper described two randomised, double-blind, placebo-controlled, ascending-dose studies in healthy adults aged 21 to 61, running for 28 and 49 days. One injection lifted mean GH two- to ten-fold for at least six days and raised IGF-1 levels 1.5- to three-fold for 9 to 11 days. CJC-1295 had an estimated half-life of 5.8 to 8.1 days, and with repeat dosing IGF-1 remained above baseline for as long as 28 days.
Regarding safety, the authors recorded no serious adverse reactions and called the compound "relatively well tolerated", noting the lower doses were tolerated best. Healthy Male, the Australian men's health organisation, summarised the adverse events from that research as injection-site reactions, headache, nausea and diarrhoea. Warmth and flushing following injection are also widely reported with GHRH analogues, which fits with a vasodilatory effect.
A second paper, by Ionescu and Frohman (JCEM, 2006), examined how continuous stimulation affects the GH rhythm in healthy men between 20 and 40 years old. Pulse frequency and size stayed normal, while trough GH increased 7.5-fold, mean GH by 46 percent and IGF-1 by 45 percent. This is relevant when thinking about side effects, because CJC-1295 with DAC lays a higher GH floor beneath the natural pulses instead of substituting for them.
The final piece of evidence is the one most online articles leave out. In 2006 ConjuChem stopped its phase 2 trial in people with HIV-associated visceral obesity after one participant died of a heart attack soon after an eleventh weekly dose. The treating doctor concluded the death was not related to CJC-1295 and put it down to undiagnosed coronary artery disease. Even so, the programme never produced an approved medicine, and no bigger human safety dataset is available.
Order Ipamorelin for Sale, Selectivity and the Ileus Studies
The idea that ipamorelin has a "clean" side effect profile goes back to a single paper, Raun and colleagues at Novo Nordisk, published in the European Journal of Endocrinology in 1998. In pigs, GHRP-6 and GHRP-2 raised ACTH and cortisol as well as GH. Ipamorelin did not, even at doses over 200 times its GH-releasing ED50, and none of the secretagogues altered FSH, LH, prolactin or TSH. That selectivity was seen in animals, yet it explains why ipamorelin became the standard ghrelin-receptor agonist for research designs in which cortisol would muddy the results.
The human evidence comes from gastrointestinal research rather than growth hormone work. Once Venkova and colleagues (JPET, 2009) had shown that ipamorelin accelerated colonic transit in rats following abdominal surgery, Helsinn developed it as a treatment for postoperative ileus. In the phase 2 trial reported by Beck and colleagues (International Journal of Colorectal Disease, 2014), 117 patients undergoing bowel resection were given intravenous ipamorelin or placebo twice a day for up to seven days. Treatment-emergent adverse events affected 87.5 percent of the ipamorelin arm and 94.8 percent of the placebo arm, a pattern that reflects a post-surgical population rather than any drug signal. The authors described it as well tolerated. Time to the first tolerated meal was 25.3 hours against 32.6 hours, but that gap was not significant, and a second, bigger Helsinn phase 2 study also finished without producing an approved product.
In short, the ipamorelin side effect evidence amounts to this. It was tolerable as an intravenous infusion given to hospital patients for a week, and no long-term or subcutaneous safety study has been published. Ipamorelin is for sale in Australia as a 10 mg vial, and every lot is backed by an independent certificate.
Buy CJC-1295 Online, Why DAC and No DAC Side Effects May Differ
Since the human trials used the DAC form, their findings do not carry over cleanly to the No DAC version that most blends contain. The DAC form keeps GH elevated for days, whereas modified GRF(1-29) creates a brief pulse much closer in shape to native GHRH. Any discussion of cjc-1295 ipamorelin side effects that leans on Teichman is therefore describing a different exposure pattern from what a No DAC blend delivers. Order the CJC-1295 and ipamorelin blend online as a single 10 mg vial from Australian stock when a protocol uses the No DAC pair.
| Compound | Target receptor | Human data in print | Main safety finding |
|---|---|---|---|
| CJC-1295 with DAC | GHRH receptor | Teichman 2006, Ionescu and Frohman 2006, and the halted HIV phase 2 | Healthy adults had no serious adverse reactions, only mild GI and injection-site events |
| CJC-1295 No DAC (mod GRF 1-29) | GHRH receptor | No specific safety trial published | Not known, brief exposure profile |
| Ipamorelin | Ghrelin receptor (GHS-R1a) | Beck 2014 ileus phase 2 (IV) | Tolerated well across 7 days, and animal studies showed no rise in ACTH or cortisol |
| CJC-1295 plus ipamorelin | Both | None | Human data on the combination do not exist |
CJC-1295 with DAC fits sustained-exposure designs and is the only version with published human pharmacokinetics. You can compare fills on the CJC-1295 with DAC 5 mg vial page and the CJC-1295 No DAC product page.
Shop Growth Hormone Peptides Online, What Studies Actually Measured
In the published research, cjc 1295 benefits are hormone readings, meaning higher GH and IGF-1 levels in the blood. Animal studies go a little further. Alba and colleagues (American Journal of Physiology, 2006) gave CJC-1295 to GHRH-knockout mice and found that daily administration brought body weight, length and body composition back to normal, along with a rise in pituitary GH mRNA. Ipamorelin benefits are likewise preclinical, covering GH release in rats and pigs and quicker colonic transit in the rat ileus model.
No clinical outcome has been demonstrated in healthy people. As Healthy Male states directly, there is no good-quality human evidence that CJC-1295 or ipamorelin builds muscle, cuts fat, speeds recovery or slows ageing, and a shift in a blood test is not a health benefit. Tesamorelin offers a useful contrast. This GHRH analogue did win approval in the United States for HIV-associated abdominal fat, which explains why the tesamorelin research peptide is frequently chosen as a comparator in GHRH research.
Order From Tested Lots, the Biggest Gaps in the Evidence
- Nothing on the combination. CJC-1295 and ipamorelin have never been given together to people in a published trial, so side effects specific to the blend have not been recorded.
- Nothing on long-term exposure. The longest CJC-1295 trial lasted 49 days, and the impact of months of elevated IGF-1 was never examined.
- No safety study of subcutaneous ipamorelin. Human trials relied on intravenous infusion in hospital patients.
- Risks to identity and purity. Unverified product may hold the wrong sequence, truncated fragments or leftover solvents, making any effect seen impossible to interpret.
A supplier can close that final gap. An independent laboratory tests every NovaPep lot for identity by mass spectrometry and purity by HPLC, and each vial's lot number matches its certificate on our COA lookup page. If those reports are new to you, our walkthrough on how to read a certificate of analysis explains what the chromatogram and mass spectrum ought to show.
Buy Ipamorelin and CJC-1295 Australia, WADA and Legal Position
On the World Anti-Doping Agency Prohibited List, both compounds sit under S2.2.4, growth hormone releasing factors, with CJC-1295 listed as a GHRH analogue and ipamorelin as a growth hormone secretagogue. Both are banned at all times, in competition and out of it. In Australia the TGA has approved neither for supply as a medicine, and neither is on the ARTG as a registered product. Check the current Poisons Standard for scheduling before doing any work outside a laboratory.
Buy CJC-1295 and Ipamorelin Online From Independently Tested Lots
Since identity risk is among the gaps outlined above, where you buy CJC-1295 or ipamorelin for a study really matters. NovaPep offers ipamorelin 10 mg, CJC-1295 No DAC 10 mg and the ready-mixed CJC-1295 and ipamorelin blend, all kept in Australian stock and for sale online. The blend works out cheaper than paying for half of each single vial. Choose separate vials when each receptor arm must be adjusted on its own, and choose the blend when your protocol already sets equal amounts of each by mass. Every lot has an independent mass spectrometry and HPLC report in the COA library, filed under the same number as the vial. Browse online, check the certificate, then place your order.
NovaPep sells CJC-1295, ipamorelin and the blend to adults 18+ only for in-vitro and laboratory research. They are not for human or veterinary use, and this page contains no dosing or treatment advice. When preparing solutions for lab work, head next to the CJC-1295 and ipamorelin reconstitution calculator and the full growth hormone peptide range.
CJC-1295 Ipamorelin Side Effects: Findings From the Human Research FAQ
Which CJC-1295 side effects came up most in research?
CJC-1295 with DAC produced no serious adverse reactions in the 2006 Teichman trials involving healthy adults. The reported events were mild, covering injection-site reactions, headache, nausea and diarrhoea, and vasodilatory flushing is also noted for GHRH analogues generally. Those trials lasted 28 and 49 days, so effects over a longer period are not known.
Is ipamorelin linked to fewer side effects than other GHRPs?
In animal studies it is. Raun and colleagues (1998) reported that ipamorelin left ACTH and cortisol unchanged in pigs, in contrast to GHRP-6 and GHRP-2, even at more than 200 times its GH-releasing ED50. No dedicated human study has checked whether that selectivity carries over to people.
Has anyone studied CJC 1295 ipamorelin side effects in combination?
No. There is no published human trial that combined CJC-1295 with ipamorelin. Claims about side effects of the blend are pieced together from separate evidence, the CJC-1295 DAC trials in healthy adults and the intravenous ipamorelin trials in surgical patients. Neither involved the No DAC form that most blends contain.
Is CJC-1295 prohibited in sport?
Yes. CJC-1295 appears on the WADA Prohibited List under S2.2.4 growth hormone releasing factors, and ipamorelin is listed in that same section as a growth hormone secretagogue. Both are banned at all times, both in and out of competition, for anyone covered by the World Anti-Doping Code.
Would CJC-1295 DAC and No DAC have different side effects?
Probably, though human data exist only for the DAC form. DAC attaches to albumin and holds GH up for around a week, whereas No DAC gives a brief pulse. Side effects tied to the prolonged GH and IGF-1 rises in the DAC trials may not apply to No DAC, which has no published safety trial.
Where can I order CJC-1295 and ipamorelin online in Australia?
NovaPep carries CJC-1295 No DAC, CJC-1295 With DAC, ipamorelin and a 10 mg blend containing 5 mg of each, all sold online from Australian stock for laboratory research only. Every lot is supplied with an independent certificate confirming identity and purity, stored under the matching lot number in our COA library. We offer no dosing, stacking or personal-use advice.